ALK and inflammatory myofibroblastic tumor: It was approved by the Food and Drug Administration for the treatment of ALK-positive non-small-cell lung cancer and inflammatory myofibroblastic tumors (Butrynski et al., 2010; O'Bryant et al., 2013).